02415 MEDSCI
- 0.960
- +0.240+33.33%
MEDSCI News
MedSci Healthcare Trustee Purchases Shares
MedSci Healthcare Advances Share Award Scheme
Meihs-kang (02415): The trustee purchased a total of 100,000 shares under the stock incentive plan.
Mei's Health (02415) announced that on September 11, 2024, the trustee purchased a total of 10 shares from the Hong Kong Stock Exchange.
The Stock Exchange of Shanghai and the Stock Exchange of Shenzhen: 33 shares will be included in the Hong Kong Stock Connect symbol from today.
The Shanghai Stock Exchange and Shenzhen Stock Exchange have announced that 33 stocks have been included in the list of Hong Kong stocks eligible for trading through the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect starting today.
MEDSCI: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024
Hong Kong stocks unusual | Meinian Health (02415) fell more than 5% to a new low. It is expected that the net profit for the first half of the year will decrease by up to 0.5 million yuan. The company may be removed from the Hong Kong Stock Connect.
After Mesoblast (02415) issued a profit warning, its stock price fell more than 5%, reaching a new all-time low of 1.42 Hong Kong dollars. The current market cap has evaporated nearly 90% from its historical peak. As of the time of writing, it dropped by 5.33%, closing at 1.42 Hong Kong dollars, with a turnover of 2.236 million Hong Kong dollars.
MedSci Healthcare Signals Profit Decline but Stays Optimistic
Meis Health (02415.HK): The company expects a decrease in net profit in the mid-term, but an increase in gross margin. The company will maintain profitability.
Gelonghui August 26th | Mes Health (02415.HK) issued an announcement that as of the six months ended June 30, 2024 ("reporting period"), the expected net profit for the reporting period will decrease from RMB 11.9 million for the six months ended June 30, 2023 ("corresponding period") to no more than RMB 0.5 million, mainly due to (i) the temporary delay in the recognition of income from the Precision Omni-Channel Marketing Solutions and Real-World Clinical Research Solutions projects due to delayed project execution, resulting in a decrease in group income for the reporting period compared to the corresponding period; (ii) there were no convertible redeemable preference shares in the corresponding period.
MEDSCI: INSIDE INFORMATIONPROFIT WARNING
MedSci Healthcare Prepares for Key Board Meeting
Meihsing Health (02415.HK) plans to hold a board of directors meeting on August 30 to review its interim performance.
Mei's Health (02415.HK) announced that the board of directors meeting will be held on August 30, 2024 (Friday), including the consideration and approval of the group's interim performance report for the six months ending on June 30, 2024, and the proposal to distribute interim dividends (if any), as well as handling other matters.
MEDSCI: DATE OF BOARD MEETING
CICC: What Is the Impact of the Half-Yearly Adjustment of the Hang Seng Index and the Hong Kong Stock Connect?
Hang Seng Index Company announced its regular semi-annual index adjustment results on August 16, 2024 (the review and assessment period ended on June 30, 2024, and the results were announced within 8 weeks after the assessment date).
Mesnac Health (02415) has been removed from the Hang Seng Composite SmallCap Index and may be removed from the Hong Kong Stock Connect.
On August 16th, Hang Seng Indexes Company announced the latest quarterly review results, in which Mason Group Holdings Limited (02415) will be removed from the Hang Seng Composite Smallcap Index. The change will be implemented after the market closes on Friday, September 6th, 2024, and will take effect on Monday, September 9th, 2024.
Snap up has started! Hong Kong medical stocks are soaring.
The long-silent medical industry has become a pioneer in the trend of track switching. In recent times, with the sharp decline in the US stock market index and the need for the dividend sector in A-share to switch, the growth strategy of public funds has once again shown the effect of making money in the Hong Kong stock market. Brokerage China News reporters noticed that in the context of China's assets becoming popular and the style of tracks switching, the Hong Kong medical industry which has experienced 3 years of in-depth adjustments, has become the main target of public funds searching for high-elasticity symbols, and even the phenomenon of all market funds abandoning other tracks to switch to pharmaceutical theme funds. Product structure, 10-30 billion yuan products operating income of 401/1288/60 million yuan respectively.
Part of the Hong Kong stock medical and healthcare stocks rose.
On August 1st, Gelonghui: Meheco rose nearly 40%, Shengnuo Medicine-B rose 15%, Lai Kai Pharmaceutical-B, Dingdang Health and other stocks rallied.
MedSci Healthcare Announces Strategic Partnership
Mei's Health (02415.HK) subsidiary Biovalley has reached a strategic cooperation with Weigao Group.
On July 19th, Health Industry Mesooon Inc. (02415.HK) announced that its subsidiary Shanghai Chungu Biomedical Technology Co., Ltd. ("Chungu Biomedical") has officially reached a strategic cooperation with Weigao Group Co., Ltd. ("Weigao Group"). The two parties will cooperate in multiple alliances, such as media promotion, park investment promotion, and strategic service alliances for industry sharing and exchange, market acceleration services, scientific research and innovation alliances, and financial services and innovation alliances. They will work together to stimulate more local innovation energy, deepen the influence of Weigao Park and the high-quality products of Weigao Group, and help Weigao Group's core competencies in the industry.
MedSci Healthcare Co-CEO Steps Down; Successor Named
MedSci Healthcare Announces Top Executive Reshuffle
Analysis
Price Target
No Data
No Data